Vertex announces national reimbursement agreement in france for kaftrio® (ivacaftor/tezacaftor/elexacaftor) and symkevi® (tezacaftor/ivacaftor) for eligible cystic fibrosis patients

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced a national reimbursement agreement with the french health authorities for the cystic fibrosis (cf) medicines kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor and symkevi® (tezacaftor/ivacaftor) in combination with ivacaftor. both medicines will be available for all eligible patients once the agreement has been published in the french official journal. “today's announcem
VRTX Ratings Summary
VRTX Quant Ranking